We are live on ! Find out more
HALO icon

Halozyme

384 hedge funds and large institutions have $4.75B invested in Halozyme in 2023 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 139 increasing their positions, 155 reducing their positions, and 79 closing their positions.

New
Increased
Maintained
Reduced
Closed

397% more call options, than puts

Call options by funds: $20.7M | Put options by funds: $4.17M

3.82% less ownership

Funds ownership: 95.63% → 91.81% (-3.8%)

9% less funds holding

Funds holding: 423 → 384 (-39)

10% less repeat investments, than reductions

Existing positions increased: 139 | Existing positions reduced: 155

32% less capital inflows, than outflows

Capital inflows: $616M | Capital outflows: $911M

43% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 79

78% less funds holding in top 10

Funds holding in top 10: 18 → 4 (-14)

Holders
384
Holders Change
-39
Holders Change %
-9.22%
% of All Funds
6.11%
Holding in Top 10
4
Holding in Top 10 Change
-14
Holding in Top 10 Change %
-77.78%
% of All Funds
0.06%
New
45
Increased
139
Reduced
155
Closed
79
Calls
$20.7​M
Puts
$4.17​M
Net Calls
+$16.5​M
Net Calls Change
-⁠$11.3​M

HALO Hedge Fund Activity: Q1 2023 in Review

384 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q1 2023, worth a combined $4.75B — down 35% from $7.35B a quarter earlier.

Sellers outnumbered buyers: 79 funds closed out of HALO and 45 opened new positions — a net loss of 34 holders — while 155 trimmed existing stakes and 139 added.

The largest buyer was ArrowMark Colorado Holdings, opening a new position worth an estimated $54.3M. The largest seller was William Blair Investment Management, exiting entirely with an estimated $211M sold.

  • 384 institutional investors held Halozyme (HALO) as of Q1 2023, down from 423 in Q4 2022.
  • Funds reported $4.75B of Halozyme stock for Q1 2023, down 35% quarter-over-quarter.
  • 45 funds opened new Halozyme positions in Q1 2023 and 79 closed out, a net change of -34 holders.
  • The largest Halozyme buyer in Q1 2023 was ArrowMark Colorado Holdings, an estimated $54.3M added.
  • The largest Halozyme seller in Q1 2023 was William Blair Investment Management, an estimated $211M sold.

Based on aggregated 13F filings for Q1 2023.